Cancer Treatment Today

For first line unresectable pleural mesothelioma, NCCN recommends: Alimta and carboplatin or cisplatin every 3 weeks as a Category 1 recommendation. In various studies, these combinations obtained overall response rate of 26.3% in 745 mesothelioma patients, and the combination of pemetrexed and carboplatin was associated with an overall response rate of 21.6%. One-year survival rate was 63 to 64%. The researchers' findings were derived from an analysis

CTCL includes a number of clinical syndromes, the most common of which are mycosis fungoides and the Sézary syndrome. Mycosis fungoides presents with patches, plaques, or tumors. In the initial stages disease is confined to the skin. Sézary syndrome is a leukemic variant of CTCL, characterized by erythroderma (stage T4), lymphadenopathy, pruritus and circulating neoplastic (Sézary) cells (stage B1). Bexarotene is FDA approved for this disease

Mesothelioma is a cancer that is most often linked to asbestos exposure. It can involve the lining of the lung (pleura) or of the belly (abdomen but are also found on the lining of the abdomen, heart or testicles. Pleural and abdominal mesotheliomas are the most common. Treating mesothelioma surgically remains difficult because it spreads along surfaces of these linings. To perform surgery, accurate tumor staging is imperative since many patients